COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm (IVA-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01022463
Recruitment Status : Completed
First Posted : December 1, 2009
Last Update Posted : July 7, 2011
Information provided by:
Govind Ballabh Pant Hospital

Brief Summary:
The purpose of this study is to study the effect of Ivabradine vs Atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm.

Condition or disease Intervention/treatment Phase
Mitral Stenosis Drug: Ivabradine Drug: Atenolol Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Ivabradine vs Atenolol on Heart Rate and Effort Tolerance in Patients With Mild to Moderate Mitral Stenosis and Normal Sinus Rhythm
Study Start Date : November 2009
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Ivabradine
Crossover study to compare ivabradine and atenolol
Drug: Ivabradine
Ivabradine 5 mg BId for 4 weeks

Drug: Atenolol
50 mg od for 4 weeks

Placebo Comparator: Atenolol Drug: Atenolol
50 mg od for 4 weeks

Primary Outcome Measures :
  1. Change in effort tolerance ( in minutes/Mets) from baseline with the study drugs at the end of stipulated 4 weeks [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Mild to moderate mitral stenosis (Mitral valve area: 1.0 cm2 - 2.0 cm2 on echocardiography) with normal sinus rhythm
  2. Age >18 years
  3. Need for rate control therapy for symptoms

Exclusion Criteria:

  1. Atrial fibrillation
  2. Other significant valvular lesions (More than mild AS/AR/MR)
  3. Denial of consent
  4. Unable to do TMT/Contraindication for TMT
  5. Need for surgical treatment or BMV
  6. Presence of significant non-cardiac co-morbidities
  7. Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01022463

Layout table for location information
G. B. Pant Hospital
New Delhi, Delhi, India, 110002
Sponsors and Collaborators
Govind Ballabh Pant Hospital
Layout table for investigator information
Principal Investigator: Dr Neeraj Parakh, MD, DM G. B. Pant Hospital, New Delhi
Additional Information:
Layout table for additonal information
Responsible Party: Dr Neeraj Parakh, Govind Ballabh Pant hospital, New Delhi, India Identifier: NCT01022463    
Other Study ID Numbers: F-2/IEC/MAMC/09/No.192
First Posted: December 1, 2009    Key Record Dates
Last Update Posted: July 7, 2011
Last Verified: November 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitral Valve Stenosis
Constriction, Pathologic
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action